New anticancer agents.
Britten
C
C
Department of Medicine/Oncology, University of Texas, Health Science Center at San Antonio 78284-7884, USA.
Hammond
L
L
Hidalgo
M
M
Rothenberg
M L
ML
Sharma
A
A
Sharma
S
S
Siu
L
L
Villalona-Calero
M
M
Weiss
G R
GR
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D004247:DNA / Q000187:drug effects; D005467:Floxuridine / Q000494:pharmacology; D006801:Humans; D008870:Microtubules / Q000187:drug effects; D009944:Organoplatinum Compounds / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014498:Uracil / Q000031:analogs & derivatives / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D005467:Floxuridine; C073482:eniluracil; D014498:Uracil; C081294:satraplatin; D004247:DNA; D013940:Thymidylate Synthase; D018844:Cyclin-Dependent Kinases; C025034:doxifluridine